Certara (NASDAQ:CERT) Reaches New 12-Month Low – Here’s Why

Certara, Inc. (NASDAQ:CERT) reached a new 52-week low on Friday . The stock traded as low as $9.25 and last traded at $9.44, with a volume of 105418 shares. The stock had previously closed at $9.78.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Stephens restated an “overweight” rating and issued a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. Barclays lifted their price objective on shares of Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. TD Cowen assumed coverage on shares of Certara in a report on Thursday, February 27th. They issued a “buy” rating and a $16.00 target price on the stock. Finally, William Blair reiterated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $15.83.

Certara Stock Down 2.8 %

The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $1.53 billion, a P/E ratio of -47.46, a PEG ratio of 9.29 and a beta of 1.64. The firm has a 50 day simple moving average of $12.22 and a two-hundred day simple moving average of $11.42.

Hedge Funds Weigh In On Certara

A number of institutional investors have recently added to or reduced their stakes in CERT. Kopion Asset Management LLC increased its position in Certara by 46.0% during the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company’s stock valued at $5,918,000 after purchasing an additional 175,005 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Certara by 3.1% in the 4th quarter. Principal Financial Group Inc. now owns 531,445 shares of the company’s stock valued at $5,660,000 after purchasing an additional 15,739 shares during the period. Vontobel Holding Ltd. bought a new position in shares of Certara during the 4th quarter worth approximately $1,295,000. Barclays PLC grew its holdings in Certara by 198.3% in the third quarter. Barclays PLC now owns 70,525 shares of the company’s stock worth $825,000 after purchasing an additional 46,880 shares during the period. Finally, Proficio Capital Partners LLC acquired a new stake in shares of Certara in the 4th quarter valued at about $148,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.